PharmaMar presents new results with lurbinectedin

(Pharmamar) PharmaMar (MSE:PHM) today announced new data on the recurrent small-cell lung cancer patients cohort of the phase II basket study with lurbinectedin as a single agent, will be presented at the American Society of Clinical Oncology (ASCO) annual meeting, being held from the 1st to the 5th of June in Chicago.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news